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Introduction: The aim of this work was to quantify the effects of injection volume at different technetium-99m specific radiotracer doses on
its lymphatic movement in animal model.
Procedures: Effects of injection volume (50, 100 μl) at different doses (0.05, 0.135, 0.22 nmol) on popliteal node (PN) detection were
studied in rats. The radiotracer under study was 99mTechnetium-cysteine-mannose-dextran conjugate (30 kDa).
Results: At 0.05 nmol dose, higher PN uptake was observed at 50 μl injection volume (2.6 fold increase). Conversely, at 0.135 nmol dose, an
increase of radiotracer retention in PN was achieved at 100 μl volume, 78% higher than 50 μl. However, at 0.22 nmol dose, the injection
volume changes did not influence on the PN uptake. Considering as suitable radiotracer performance: high PN uptake and extraction, better
combinations were 0.05 nmol/50 μl, 0.135 nmol/100 μl, 0.22/50 μl.
Conclusion: Suitable performances could be reached by proper combinations of dose, injection volume and concentration for a specific
radiotracer used in sentinel lymph node detection.
Crown Copyright © 2012 Published by Elsevier Inc. All rights reserved.Keywords: Sentinel lymph node detection; Technetium-99m; Tissue-specific radiopharmaceutical; Dosage; Injected volume1. Introduction
Since 1992, sentinel lymph node biopsy have been
extensively used in patients with breast cancer and cutaneous
malignant melanoma [1]. Nowadays, the application of this
technique for lymphatic metastasis diagnostic is expanding
in other kinds of cancer like prostate, gynecological,
gastrointestinal and oral/oropharyngeal squamous cell car-
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doi:10.1016/j.nucmedbio.2011.07.004Sentinel lymph node detection is basically performed by
use of technetium-99m radiocolloids, noncarcinogenic inert
dyes and [F-18] 2-deoxy-2-fluoro-d-glucose (FDG) [5,6].
The first two classes of compounds can be used separately,
but better results are obtained when they are used together
[7]. The nodal staging with technetium-99m radiopharma-
ceuticals and dyes leads to an invasive approach for
histological studies. Conversely, positron emission tomog-
raphy with FDG is not invasive but it has a poor sensitivity
for detecting millimetric metastasis in lymph nodes [8].
Therefore lymph node biopsy is still the technique of choice
for defining whether or not cancer cells have entered
lymphatic system.
A new concept of technetium-99m radiopharmaceuti-
cals for sentinel lymph node identification emerged with
Lymphoseek. This radiotracer in clinical trials is the first
tissue specific radiopharmaceutical for this purpose. This
dextran-based product has long-lasting selectivity for
mannose receptors expressed on macrophages andInc. All rights reserved.
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seek meets three important properties for a suitable
sentinel lymph node agent: fast clearance from injection
site, rapid accumulation with prolonged retention in
sentinel lymph node and low uptake in other nodes of
lymphatic chain [10].
Nevertheless, the satisfactory performance of radiotracer
for sentinel node detection not only depends on its own
properties. In that sense injection site, injection activity,
injection volume and utilization of imaging should be also
considered [11,12]. Specifically, the injection volume can
influence in a negative or positive way the lymphatic
performance of radiotracers due to the fragile balance
between internal and external pressures in a lymphatic
channel [13].
Preclinical and clinical studies about the combined impact
of injection dose or activity and volume in sentinel node
agent performance have not been widely considered.
The aim of this paper was to evaluate the effects of
injection volume at different technetium-99m specific
radiotracer doses on its biological performance in a rat model.2. Materials and methods
2.1. Materials
Na[99mTcO4] was eluted from
99Mo/99mTc generator
(Institute of Energetic and Nuclear Research, IPEN/CNEN-
SP, Brazil), using 0.9% saline. The [99mTc(OH2)3(CO)3]
+
was prepared from Isolink kit (Covidien, Petten, The
Netherlands) and Vital dye for combined technique
(sodium patent blue V, 2.5%) was donated from Guerbet
(Roissy, France).Fig. 1. Chemical structure of 2-propyThe modified dextran, 2-propylene-cysteine-mannose-
dextran [Fig. 1], with chemical purity higher than 95% were
provided without cost by National Center for Scientific
Research “Demokritos” Athens, Greece. Its molecular
weight is 30 KDa with 9 and 36 units of cysteine and
mannose respectively.
Forty-eight young female Wistar EPM-1 rats were
provided by the Animal Facility of IPEN-CNEN, weight
ranging from 150 g to 200 g. Animal studies were performed
at the Radiopharmacy Center, IPEN/CNEN, and the protocol
was accepted by the animal Welfare Ethical Committee.
2.2. Preparation of the precursor [99mTc(OH2)3(CO)3]
+
[99mTc(OH2)3(CO)3]
+ was prepared from Isolink kit,
adding 1 ml of Na[99mTcO4] (1000 MBq) as manufacturer's
instructions . The pH was neutralized with 320 μL of 1M
phosphate buffer/HCl 1N (1:2) at the end of this radiochem-
ical reaction.
2.3. Radiolabeling of dextran conjugate
Twenty microliters of 2-propylene-cysteine-mannose-
dextran aqueous solution (1 μg/μl) were mixed with 100
μl precursor [99mTc(OH2)3(CO)3]
+ (74 MBq) during 60 min
at 100°C. Each radiolabeling was carried out in triplicate.
2.4. Radiolabeling quality control
The radiochemical purity of the 99mTc-modified
dextran was determined by means of instant thin layer
and paper chromatographies. Thin layer chromatography
was carried out silica gel impregnated glass fiber sheets
(ITLCTM-SG, Pall Corporation, New York, NY, USA)
with Methanol/HCl (99:1) as mobile phase. Retention
factors (Rf) in this chromatography system for
99mTcO4,lene-cysteine-mannose-dextran.
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+ and radiolabeled dextran were 1, 1
and 0 respectively. Paper chromatography was performed
on Whatman 1 (RJM Sales Inc., New York, NY, USA)
with acetone. 99mTcO4 only migrated (Rf=1) from the
sample application point.
The radioactive profile throughout the ITLC-SG and
paper strips was measured in AR-2000 radio-Thin-Chro-
matography Imaging Scanner (Bioscan Inc., Washington,
DC, USA).
The specific activity of radiotracers was calculated by
means of activity per dextran unit weight and radiochemical
purity [14].
The dextran conjugate was also characterized by reverse-
phase high performance liquid chromatography (RP-HPLC),
including [99mTc(OH2)3(CO)3]
+ precursor. Analysis was
performed on LC-10 AT VP Liquid chromatograph
(Shimadzu, Kyoto, Japan) equipped with in-line flow
scintillation analyzer (Shell Jr. 1000/2000, VA, USA).
HPLC solvents consisted of H2O containing 0.1% trifluor-
oacetic acid (Solvent A) and methanol containing 0.1%
trifluoroacetic acid (Solvent B). A C-18 column (5.0 μm,
100 Å, 4.6×250 mm, Waters, Milford, MA, USA) was
employed with volumetric flow rate of 1 ml/min. HPLC
gradient began with a solvent composition of 95% A and was
followed by a linear gradient to 30%A: 70%B from 1 to 25
min, and 30%A:70%B to 5%A:95%B from 25 to 28 min.
2.5. Cysteine and histidine challenge
Stability of the labeled compound was assessed using
plasma concentration of cysteine (264 μM) [15] and histidine
(94 μM) [16] in PBS 0.1 M pH=7.4. Radioconjugate was
incubated incubated with an excess amount of both
aminoacids (1000-fold molar excess compared to the dextran
conjugate) at 37°C for 90 minutes. For transchelation studies
the technetium-99m conjugate was not purified. A sample
without radiotracer was used as a control. When statistical
differences were detected between control and radioconju-
gate samples, the transchelation percentage was calculated.
The amino acids transquelation was quantified by thin layer
and paper chromatography described previously (section
2.4). Technetium-cysteine and technetium-histidine have
Rf=1 in thin layer chromatography system (ITLC-SG/
Methanol/HCl (99:1)).
2.6. Lymphoscintigraphy and ex-vivo uptake study in rats.
Effects of injection volume and dose
The rats were anesthetized using 25 mg/kg tiletamine
hydrochloride associated with 25 mg/kg zolazepam hydro-
chloride administered intraperitoneally. Afterwards 0.05 or
0.1 ml with different doses (0.05; 0.135; 0.22 nmol) of
radioconjugate preparation was subcutaneously injected in
the footpad central point of the left posterior limb. Each
combination of injection volume and dose was performed
in triplicate.Images at 30 minutes post injection were performed in a
Mediso Imaging System, Budapest, Hungria, employing a
low-energy high-resolution collimator using a 256×256×16
matrix size with 20% energy window set at 140 keV.
A second injection with 0.05 ml vital dye was
administered in the footpad in similar area of the radiotracer
injection, five minutes before sacrifice time (30 minutes).
Blood samples were taken by cardiac puncture. Then,
after sacrifice the popliteal region was incised permitting
access and remotion of the popliteal lymph node. Laparot-
omy with removal of inguinal lymph node, kidneys and liver
was done at the same time. Muscle and bone tissues and
injection site were also analyzed. The radioactivity of organs
and tissues were determined by γ-counting using as standard
the injected dose of radiotracer. Results were expressed as
percentages of injected dose per organ (%ID), injected dose
per gram (% ID/g) or (nmol/g, nmol/ml).
Popliteal extraction was also calculated as the following
equation [17]:
Popliteal extracion =
UptakePopliteal LN kID½  − Uptakeinguinal LN kID½ 
UptakePopliteal LN kID½ 
× 100
2.7. Ex-vivo uptake study in rats. Massage effect on
radiotracer biodistribution over the course of 24 hours
post-injection
The procedure was almost similar with the described one
in section 2.4. The modifications were a massage for 1 min
after radioconjugate injection, the injection volume and dose
were 0.05 ml and 0.05 nmol respectively, the biodistribution
studies were carried out at 15, 30, 60, 90, 1080 and 1440 min
post injection.
2.8. Influence of radiochemical purity on
radiotracer biodistribution
The radioconjugate was previously purified (99.5%) by
means of size exclusion chromatography, in PD-10 column.
Injected volume and dose were 50 μl and 50 nmol
respectively. A gentle massage was performed for 1 min
after injection. The biodistribution was assessed 30 min p.i.,
five animals were included in this study.
2.9. Statistical analysis
Comparisons of two means were performed by t-student
test for independent samples at 0.05 level of significance
(α=0.05). One way ANOVA was carried out to determine
differences among three or more means (α=0.05). Turkey’s
test was used to define which means are significantly
different. The software used for this purpose was Stat-
graphics Plus 5.0 (Statistical Graphics Corp., Fairfax, VA,
U.S.A.). All the bar graphics were generated using Origin
8 SR2 (OriginLab Corporation, Northampton, MA, U.S.A.).
ig. 2. Phase reverse-high performance liquid chromatography profile of
purities and technetium radioconjugate. A: 99mTcO4 (tr=4.0 min). B:
99mTc(OH2)3(CO)3]
+ (tr=17.6 min). C: Technetium dextran-cysteine
onjugate (tr=11 min).
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3.1. Preparation of the precursor [99mTc(OH2)3(CO)3]
+
and dextran conjugate radiolabeling
The [99mTc(OH2)3(CO)3]
+ and 99mTc-cysteine-mannose-
dextran radioconjugate were obtained with higher than 99%
and 90.7±0,67 % (n=8) radiochemical purities respectively.
These values were calculated by combination of instant thin
layer (ITLC-SG/Methanol/HCl (99:1)) and paper (Whatman
1/acetone) chromatography and confirmed by high perfor-
mance liquid chromatography [Fig. 2]. The specific activity
of the radioconjugate was 3.36±0.02 MBq/μg or 100.8 106
GBq/mol (n=8).
3.2. Cysteine and histidine challenge
The 99m-technetium transchelation from dextran radio-
complex to cysteine (1.7 % P=.153 NS) and histidine (0.6%
P=.342 NS) and/or re-oxidation to [99mTcO4]
- after 90
minutes at plasma concentration of these amino acids and
high molar ratio (1000:1) were not detected.
3.3. Lymphoscintigraphy and ex-vivo uptake study in rats.
Effects of injection volume and dose
The injection volume effect on the popliteal lymph
node uptake was different within dose range under study
[Fig. 3A]. At lower dose (0.05 nmol), higher uptake was
observed at 50 μl injection volume (2.6 fold increase,
P=.015). Conversely, at intermediate dose (0.135 nmol),
an increase of radiotracer retention in popliteal node was
achieved at 100 μl volume, 78% higher (P=.003) than 50
μl. However, at 0.22 nmol dose, the injection volume
changes did not influence on the popliteal node uptake
(P=.352 NS).
Popliteal extraction was also modulated by injection
volume. Lower volume at 0.05 nmol dose improved
significantly (1.73 fold, P=.009) this parameter respect to
100 μl injection volume. Similarly, at 0.22 nmol dose, high
injection volume decreased in 55% (P=.003) the popliteal
extraction. No modification in radiotracer popliteal extrac-
tion at intermediate dose for both assessed injection volumes
was detected (P=.071) [Fig. 3B].
Considering as suitable radiotracer performance: high
popliteal lymph node uptake and extraction, the radiotracer
amounts retained in better injection volume for each dose
were 0.0024±0.0008 nmol (0.05 nmol/50 μl), 0.0044±0.0004
nmol (0.135 nmol/100 μl) and 0.0055±0.0008 nmol (0.22
nmol/50 μl). An increase in amount retained was observed
(P=.0050) from 0.05 nmol to 0.22 nmol but differences were
not detected between 0.135 and 0.22 nmol as Turkey’s test
[Fig. 4]. This suggests popliteal node saturation at 0.135 and
0.22 nmol doses with proper injection volumes.
The radiotracer uptakes in important excretions organs
like liver and kidneys were not modified by injection volume
in the range of dose evaluated in this study. Similar
performance was detected for bone and muscle tissuesF
im
[
cwhereas in blood, the injection volume effect was only
detected at 0.05 nmol dose (P=.018). Nevertheless, radioac-
tivities in three last biological compartments were low in all
cases [Table 1].
The radioconjugate migration from injection site (% ID)
was independent of dose and injection volume (P=.968 NS)
[Table 1].
Scintigraphic Images corresponding to six combinations
of dose and injection volume allowed detecting both
Fig. 3. Influence of injection volume (50, 100 μl) at different doses on
popliteal lymph node uptake (A) and popliteal extraction (B) at 30 minutes
post-injection. Variables averages±standard deviations are represented
(n=3).
ig. 4. Absolute popliteal uptakes for better radiotracer performances in each
ose. The injection volumes for 0.05, 0.135 and 0.22 nmol doses were 50,
00, 50 μl respectively. Bars represent the confidence intervals for Tukey
st (α=0.05)
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the ex-vivo results regarding popliteal lymph node uptake
and extraction.
3.4. Ex-vivo uptake study in rats. massage effect on
radiotracer biodistribution over the course of 24 hours
post-injection
The massage effect on the biological performance of
99mTc-dextran conjugate was assessed at 0.05 nmol dose and
50 μl injection volume because suitable results were
obtained with these conditions without massage.
The massage effect was significant for improving
radiotracer migration from the injection site (P=.017).
After 30 min post injection, a 15.79% ID decrease from
injection site was observed when massage was carried out
[Tables 1-2]. However, neither popliteal lymph node uptake
(P=.518 NS) nor popliteal extraction (P=.251 NS) were
enhanced with massage. The other organs, tissues and blooddid not also show differences in uptakes with or without
massage [Fig. 3,6] [Tables 1-2].
A similar uptake profile for popliteal node and liver over
24 hours post-injection was confirmed. The maximum
uptakes for both anatomical elements had a 30 minutes
delay and the uptake decrease at the end of study time was
more pronounced in popliteal lymph node than liver [Fig. 6].
The radiotracer retention in kidneys, blood, and bone and
muscle tissues was stable during 24 hours post-injection.
Similar behavior showed the injection site over the course of
90 minutes after injection.
3.5. Influence of radiochemical purity on radiotracer
biodistribution
No statistical differences between lymph nodes and main
excretion organs uptakes as well as radiotracer migration
from injection site for purified and non purified radio-
conjugate were detected (Table 3). The blood, bone and
muscle uptakes for purified product were 0.10±0.04 %ID/ml;
0.06±0.01 %ID/g; 0.01±0.01 %ID/g respectively. These
values are similar to the observed for non purified
radiotracer, 30 min p.i. (Table 2).4. Discussion
Site-specific radiocompounds to demonstrate occupancy
of a target site such as receptor-binding radiotracers has
became a major component in drug development process and
nuclear medicine diagnostic procedures [18,19]. Specifical-
ly, for lymph node detection, a novel molecular imaging
agent based on receptor-binding property, Lymphoseek, has
been designed. This radiopharmaceutical opens new possi-
bilities for lymphatic system agents, until now they have
been primarily designed taking into account their particle
size (radiolabeled colloids) together with functional and
mechanical properties of the lymphatic system [20].
Therefore, the suitable tracer performance in sentinel nodeF
d
1
te
Table 1
Biodistribution study for different doses and injection volumes of the radioconjugate at 30 minutes post injection
Dose
(nmol)
Volume
(μl)
Uptakes
Injection site (% ID) Liver (% ID) Kidneys (% ID) Blood (% ID/ml) Bone (% ID/g) muscle (% ID/g)
0.05 50 64,73±2,24 3,14±0,42 0,68±0,18 0,26±0,03 0,09±0,01 0,04±0,01
100 66,77±2,62 2,71±0,18 0,46±0,09 0,20±0,02 0,08±0,03 0,04±0,01
0.135 50 64,40±3,19 2,42±0,48 0,42±0,04 0,24±0,04 0,07±0,02 0,03±0,01
100 63,42±10,58 2,93±0,42 0,40±0,08 0,13±0,06 0,12±0,03 0,04±0,01
0.22 50 62,59±7,85 2,72±0,37 0,39±0,12 0,16±0,04 0,11±0,07 0,02±0,01
100 64,52±3,31 3,43±0,83 0,44±0,06 0,15±0,03 0,10±0,05 0,04±0,03
The results were expressed as average±standard deviation are shown (n=3).
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parameters related with lymphatic functioning like injection
volume and dose must be considered [21,22]. In literature, it
can find different radiotracers for this purpose with good
clinical results by means of a proper selection of the related
variables with the biological performance, despite of
pronounced molecular differences.
In addition to specificity elements, site-specific radio-
tracers also need an appropriated synthetic route for
radionuclide incorporation. In that sense, our group
previously optimized radiolabeling conditions for 2-propyl-
ene-cysteine-mannose-dextran with precursor [99mTc(OH2)3
(CO)3]
+. The criteria taken in consideration were high
radiochemical purity and concentration, rapid radiolabeling
and high specific activity.
The radiochemical yield was 91%, this value is within
reported range for other 99mTc-mannose-dextran conjugate
using mercapto-acetyl-tri-glycine chelator (MAG3) [23] but
it is lower than values usually reported for Lymphoseek
(N98%) [17]. Specific activity (101×106 GBq/mol), another
important radiochemical parameter, was higher than those
observed for radiotracers using MAG3 (22.3×106 GBq/mol)Fig. 5. Static images for six combinations of injection volume and dose after
30 minutes. Dose of 0.05 nmol and injection volumes of 50 and 100 μl
respectively are represented in A and B. Dose of 0.135 nmol and similar
increasing volumes are showed in C and D respectively. Dose of 0.22 nmol
and 50 and 100 μl injection volumes correspond to E and F images. Popliteal
node (p.n.), inguinal node (i.n.).[23] but inferior than values shown for diethylenetriamine-
pentaacetic acid-mannose-dextran conjugate (Lymphoseek)
(5.3×109 GBq/mol) [17]. In addition, the radiotracer 99mTc-
2-propylene-cysteine-mannose-dextran avidity for mannose
receptors in lymph node cells was in vivo demonstrated [24].
The 99m-technetium transchelation absence to cysteine
and histidine in plasma concentrations at high molar ratio
(1000:1) suggests a poor background effect in image
studies for this radiotracer. In fact, the protein concentra-
tion of lymph is usually less concentrated than, that of
blood plasma [25]. In this experiment was also confirmed
no chelating reaction between both amino acids because
[99mTc(OH2)3(CO)3]
+ percentage kept constant. Thus,
protein radiolabeling in biological fluids (in situ) is
unlikely over first 90 min post-injection. In addition, low
protein lymph binding and rapid migration from the
injection site are expected because of the marked
hidrophilicity of the radiotracer (Log P=-2.144) (property
previously determinate by our group) [24].
The injection of radiotracers into the foot pads of healthy
mice, rats or rabbits has been useful to determine the
lymphatic movement of these products directed to sentinel
node detection [17,26,27]. In general, these models in healthy
animals are used during the initial phase of preclinical studies
where a new radiocompound is contrasted with one or various
established radiopharmaceuticals. Three parameters are
mainly considered when injection is performed in rear foot
pads: popliteal lymph node uptake, popliteal extraction and
remaining radioactivity in injection site. The assessed
radiotracer performance in this model defines the continuity
of preclinical studies in more complex animal models to
investigate lymph node metastases. In the present work, a
variant of this model in rat was used to quantify the effects of
dose and injection volume for a specific sentinel node
radiotracer on its lymphatic movement and lymph nodes
uptakes. Influences of injection volume and dose have been
investigated in preclinical and even in clinical assays [28,29]
but combined effects of both parameters in radiotracers for
lymph node detection have not still explored.
In vivo experiments demonstrated that the uptake in
popliteal lymph node, the nearest node from the injection
site, was influenced by the injection volume, radiotracer
concentration and dose. To define the actual effect of each
variable, experimental data was analyzed by injected dose.
Table 2
Radioconjugate biodistribution over the course of 24 hours (1440 min) post injection
Time
(min)
Popliteal
Extraction (%)
Uptakes
Injection site (% ID) Kidneys (% ID) Blood (% ID/ml) Bone (% ID/g) muscle (% ID/g)
15 91,40±8,19 54,35±4,64 0,36±0,06 0,22±0,10 0,12±0,04 0,04±0,01
30 88,07±9,63 48,94±9,02 0,47±0,27 0,25±0,13 0,13±0,05 0,04±0,02
60 91,05±9,65 46,35±3,16 0,41±0,09 0,22±0,11 0,11±0,04 0,03±0,00
90 91,10±6,63 48.24±3.41 0,37±0,11 0,20±0,09 0,10±0,07 0,03±0,01
1080 88,68±9,56 - 0,51±0,13 0,11±0,09 0,05±0,04 0,02±0,00
1440 87,87±14,05 - 0,51±0,25 0,12±0,09 0,04±0,02 0,01±0,00
Dose and injection volume were 0.05 nmol and 50 μl respectively. Gentle massage was performed for 1 minute after injection. The results were expressed as
average±standard deviation are shown (n=5).
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rapid radiotracer migration and retention from injection site
for 100 μl, it was not observed [Fig. 3A]. This phenomenon
could be justified by the low radioconjugate concentration
(0.5 μM). The concentration effect has been mentioned in
literature related with non-specific radiopharmaceutical for
lymph node detection [30]. In specific receptor-binding
radiotracer for this purpose, the concentration effect is also
important because the radiotracer binding to cellular receptor
depends on free concentration of the radiomolecule [18].
At intermediate dose (0.135 nmol), the injection volume
effect is well observed, because 50 μl injection volume
showed a lower uptake respect to 100 μl volume [Fig. 3A].
The concentration in 100 μl was 1.35 μM, it was similar to
that presented by 0.05 nmol and 50 μl injection volume (1.0
μM). We hypostatize concentrations above 1 μM of 99mTc-
2-propylene-cysteine-mannose-dextran are necessary for
suitable sentinel lymph node detection.
At 0.22 nmol dose, receptors saturation is suggested
because similar popliteal lymph node uptakes were detected
with both injection volumes [Fig. 3A].Fig. 6. Popliteal lymph node and liver uptakes of the radiotracer over the
course of 24 hours (1440 min) post-injection. Injected dose: 0.05 nmol,
injection volume: 50 μl and gentle massage during 1 min post-injection.
Variables averages±standard deviations are represented (n=5).Summarizing, the expected positive effect for 100 μL
volume on popliteal lymph node uptake was not always
confirmed for three doses under study. Higher volumes favor
the radiotracer migration because pressure outside of lym-
phatic capillary increase, allowing fluid to enter the lymphatic
capillary [29]. However, effects of radiotracer concentration
and amount (dose) modified the hoped performance.
Popliteal extraction defines the preferential uptake in
sentinel lymph node respect to the second lymph node in
lymphatic chain. Therefore, high values of this parameter are
desirables. In rat model, this can be translated as higher
popliteal node uptake respect to inguinal lymph node.
Popliteal extraction at 0.05 nmol dose was improved at
low injection volume (50 μl). This could be explained by the
lower concentration and rapid migration at 100 μl volume. In
these conditions the radiotracer is more likely to migrate to
inguinal lymph node and present similar uptakes in both
lymph nodes.
At intermediate dose, no differences were detected at both
injection volumes. The mannose receptors in popliteal lymph
node could not be totally filled by the radiotracer; hence it is
just observed a high popliteal node uptake at 100 μl injection
volume. However, at 0.22 nmol dose, as probably the popliteal
lymph node saturation is reached, then the radiotracer can
better migrate to inguinal node at 100 μl volume. Thus, the
popliteal extraction decreases in these conditions.
Since radiotracer amount retained in politeal lymph node
kept stable in better conditions (high popliteal node uptake
and extraction) for 0.135 and 0.22 nmol despite the
concentration increase, 1.35 μM and 4.4 μM respectively,able 3
adioconjugate biodistribution with high radiochemical purity (99.5%), and
atistical comparisson with radioconjugate lacking further purification step
0.7±0,67%) (Table 2 and Fig. 3A)
rgan Uptake (% ID) P values (t-student)
opliteal lymph node 3.41±1.77 0,3844
guinal lymph 1.10±1.17 0,3602
idneys 0.48±0,20 0,9605
iver 2.58±1.10 0,8318
jection site 59.89±7.43 0,0901
ssessed dose, injection volume and time p.i. were 0.05 nmol, 50 μl and 30
in respectively.T
R
st
(9
O
P
In
K
L
In
A
m
152 E.G.F. Núñez et al. / Nuclear Medicine and Biology 39 (2012) 145–153probably the receptors saturation was achieved. Another fact
confirming this hypothesis is the similar absolute uptake
reported for sentinel lymph node saturation in a clinical trial
with Lymphoseek (11.0±8,5 pmol) [28]. Making an analogy
with in-vitro saturation binding assay, free radiotracer
concentrations in lymph for both situations are in plateau
region of the saturation binding curve [31], where the
maximum number of receptors on the cells (Bmax) detected
by radiotracer is a 4.4-5.5 pmol range.
All the partial conclusions related to dose and injection
volume for this subcutaneous injection can change for other
tissues in the same specie (rat) or even in a similar tissue for
humans because lymphatic flow modifications depend on
tissue density [29]. Nevertheless, radiotracer concentrations
in injection solution higher than 1 μM are recommended
regardless tumor anatomical site, injection site or specie. For
this concentration range, the mannose receptor-radiotracer
complex formation is favored and an increase of product
uptake in sentinel lymph node could be observed. The
accurate definition of these three parameters in human
tumors needs more experiments in other animal models,
while considering the present difficulties in the establish-
ment of appropriated animal models for lymph node
metastases [32]. However, it was demonstrated that different
combinations of doses and injection volumes for a bio-
specific radiotracer could show proper performances in
sentinel node detection.
The high relative uptake of the liver respect kidneys in
spite of radiotracer hidrophilicity is due to similar mannose
receptors are found in hepatic cells [33].
As good definition images were obtained at three doses
under study with proper injection volume [Fig. 5A,D,E], we
decided to continue the study with low dose.
When massage was applied in injection site at 0.05 nmol
and 50 μl injection volume, the most important change was
detected in injection site clearance of radioconjugate. The
lymphatic flow was favored by massage without affect
popliteal lymph node uptake and extraction. As radiotracer
concentration kept constant, the lymphatic environment
conditions did not also change, so both parameters remained
constant. The mechanical action of massage may also just
lead a radiotracer migration by lymphatic vessels through
lymph nodes or their surface without discharging lymph into
the node [13].
The similar uptake profile for popliteal lymph node and
liver could be attributed to similar receptor-mediated
endocytosis [34] and the 30 min delay may be due to
the anatomical distances and physiological way from
injection site.
Finally, it was demonstrated that the radiotracer purity for
values higher than 90 % do not change the biodistribution
pattern, 30 mi p.i. This means the pertechnetate ion, [99mTc
(OH2)3(CO)3]
+ precursor and any labeled macromolecule in
situ are not significantly retained neither lymph nodes nor
main excretion organs, 30 mi p.i. This outcome allows the
radioconjugate use without purification step after radiolabel-ing and confirms the previous conclusions related with
injection volume and dose.5. Conclusion
Similar suitable performances could be reached by
different combination of dose, injection volume and
concentration for a specific radiotracer used in lymph node
detection. When a critic concentration (1 μM) in adminis-
trated dose is achieved for 99mTc-cysteine-mannose-dextran
(30 KDa), combinations of high doses/low injection volume
or low dose/high injection volume are recommended. This
methodology used and the derived results could serve as a
guide for improving receptor specific radiopharmaceuticals
performance in sentinel lymph node detection both animals
and humans. However, the adjusted parameters in this study
could change according to the radiotracer properties like size
and receptors affinity as well as tissue density around
injection point.Acknowledgments
The authors are indebted to the National Commission for
Nuclear Energy (CNEN, São Paulo, Brazil), National
Counsel of Technological and Scientific Development
(CNPq, Brasília, Brazil), the International Atomic Energy
Agency (IAEA, Vienna, Austria), Covidien and Guerbet for
scientific grants and reagents donation.References
[1] Alkureishi LWT, Burak Z, Alvarez JA, Ballinger J, Bilde A, Britten
AJ, et al. Joint practice guidelines for radionuclide lymphoscintigraphy
for sentinel node localization in oral/oropharyngeal squamous cell
carcinoma. Eur J Nucl Med Mol Imaging 2009;36:1915–36.
[2] Brenot-Rossi I, Rossi D, Esterni B, Brunelle S, Chuto G, Bastide C.
Radioguided sentinel lymph node dissection in patients with localised
prostate carcinoma: influence of the dose of radiolabelled colloid to
avoid failure of the procedure. Eur J Nucl Med Mol Imaging 2008;35:
32–8.
[3] Adib T, Barton DPJ. The sentinel lymph node: relevance in
gynaecological cancers. Eur J Surg Oncol 2006;32:866–74.
[4] Yanagita S, Natsugoe S, Uenosono Y, Arigami T, Arima H, Kozono T,
et al. Detection of micrometastases in sentinel node navigation surgery
for gastric cancer. Surg Oncol 2008;17(3):203–10.
[5] Schauer AJ, Becker W, Reiser M, Possinger K. The sentinel lymph
node concept. Würzburg, Germany: Springer-Verlag; 2005.
[6] Fehr MK, Hornung R, Varga Z, Burger D, Hess T, Haller U, et al.
Axillary staging using positron emission tomography in breast cancer
patients qualifying for sentinel lymph node biopsy. Breast J 2004;10
(2):89–93.
[7] Strickland AH, Beechey-Newman N, Steer CB, Harper PG. Sentinel
node biopsy: an in depth appraisal. Crit Rev Oncol Hematol 2002;44:
45–70.
[8] Belhocine T, Driedger A. 18F-fluorodeoxyglucose positron emission
tomography in oncology: advantages and limitations. In: & Hayat MA,
editor. Cancer Imaging: Instrumentation and Applications. California:
Elsevier Academic Press; 2008, pp. 193–200.
153E.G.F. Núñez et al. / Nuclear Medicine and Biology 39 (2012) 145–153[9] Coughlin A, Resto VA. Oral cavity squamous cell carcinoma and the
clinically N0 neck: the past, present, and future of sentinel lymph node
biopsy. Curr Oncol Rep 2010;12:129–35.
[10] Ellner SJ, Méndez J, Vera DR, Hoh CK, Ashburn WL, Wallace AM.
Sentinel lymph node mapping of the colon and stomach using
Lymphoseek in a pig model. Ann Surg Oncol 2004;11:674–81.
[11] Styblo T, Aarsvold JN, Grant SF, Cohen C, Larsen T, Waldrop S, et al.
Sentinel lymph nodes: optimizing success. Semin Roentgenol 2001;
36:261–9.
[12] Aarsvold JN, Alazraki NP. Update on detection of sentinel lymph nodes
in patients with breast cancer. Semin Nucl Med 2005;35:116–28.
[13] Tanis PJ, Nieweg OE, Valdés Olmos RA, Kroon BBR. Anatomy and
physiology of lymphatic drainage of the breast from the perspective of
sentinel node biopsy. J Am Coll Surg 2001;192:399–409.
[14] Zeevaart JR, Olsen S. Recent trends in the concept of specific activity:
Impacton radiochemical and radiopharmaceutical producers. Appl
Radia Isotopes 2006;64:812–4.
[15] Obled C, Papet I, Breuillé D. Sulfur-containing amino acids and
glutathione in diseases. In: & Cynober LA, editor. Metabolic and
therapeutic aspects of amino acids in clinical nutrition. Florida: CRC
Press; 2004, pp. 667–88.
[16] Brody T. Nutritional Biochemistry. 2nd ed. California: Academic
Press; 1999.
[17] Vera DR, Wallace AM, Hoh CK, Mattrey RF. A synthetic
macromolecule for sentinel node detection: 99mTc-DTPA-Mannosyl-
Dextran. J Nucl Med 2001;42:951–9.
[18] Patel S, Gibson R. In vivo site-directed radiotracers: a mini-review.
Nucl Med Biol 2008;35:805–15.
[19] Vallabhajosula S, Owunwanne A. Pathophysiology and mechanisms
of radiopharmaceutical localization. In: & Elgazzar AH, editor. The
pathophysiologic basis of nuclear medicine. Germany: Springer; 2006,
pp. 29–49.
[20] Schöder H, Glass EC, Pecking AP, Harness JK, Wallace AM, Hirnle P,
et al. Molecular targeting of the lymphovascular system for imaging
and therapy. Cancer Metastasis Rev 2006;25:185–201.
[21] Knapp DW, Adams LG, DeGrand AM, Niles JD, Ramos-Vara JA, Weil
AB, et al. Sentinel lymph node mapping of invasive urinary bladder
cancer in animal models using invisible light. Eur Urol 2007;52:1700–9.
[22] van Esser S, HobbelinkM, Van Isselt JW, Mali WPThM, Borel Rinkes
IHM, van Hillegersberg R. Comparison of a 1-day and a 2-day protocol
for lymphatic mapping and sentinel lymph node biopsy in patients with
nonpalpable breast cancer. Eur J Nucl Med Mol Imaging 2009;36:
1383–7.[23] Vera DR, Wallace AM, Hoh CK. [99mTc]MAG3-mannosyl-dextran: a
receptor-binding radiopharmaceutical for sentinel node detection. Nucl
Med Biol 2001;28:493–8.
[24] Fernández Núñez EG, Teodoro R, Wiecek DP, da Silva NG,
Martinelli JR, de Oliveira Filho RS. Size and specificity of
radiopharmaceuticals for sentinel lymph node detection. Acta Radiol
2011;52:774–8.
[25] Swartz MA. The physiology of the lymphatic system. Adv Drug Deliv
Rev 2001;50:3–20.
[26] Fernández Núñez EG, Faintuch BL, Teodoro R, Wiecek DP, Martinelli
JR, da Silva NG, et al. Influence of colloid particle profile on sentinel
lymph node uptake. Nucl Med Biol 2009;36:741–7.
[27] Jeong JM, Hong MK, Kim YJ, Lee J, Kang JH, Lee DS, et al.
Development of 99mTc-neomannosyl human serum albumin (99mTc-
MSA) as a novel receptor binding agent for sentinel lymph node
imaging. Nucl Med Commun 2004;25:1211–7.
[28] Ellner SJ, Hoh CK, Vera DR, Darrah DD, Schulteis G, Wallace AM.
Dose-dependent biodistribution of [(99m)Tc]DTPA-mannosyl-dextran
for breast cancer sentinel lymph node mapping. Nucl Med Biol
2003;30(8):805–10.
[29] Wawroschek F, Wengenmair H, Senekowitsch-Schmidtke R, Hamm
M, Henke J, Schönberger T, et al. Prostate lymphoscintigraphy for
sentinel lymph node identification in canines: reproducibility, uptake,
and biokinetics depending on different injection strategies. Urol Res
2003;31:152–8.
[30] Vermeeren L, Muller SH, Meinhardt W, Valdés Olmos RA.
Optimizing the colloid particle concentration for improved
preoperative and intraoperative image-guided detection of sentinel
nodes in prostate cancer. Eur J Nucl Med Mol Imaging 2010;37:
1328–34.
[31] Bigott-Hennkens HM, Dannoon S, Lewis MR, Jurisson SS. In vitro
receptor binding assays: general methods and considerations. Q J Nucl
Med Mol Imaging 2008;52:1–9.
[32] Servais EL, Colovos C, Bograd AJ, White J, Sadelain M, Adusumilli
PS. Animal models and molecular imaging tools to investigate lymph
node metastases. J Mol Med 2011;89:753–69.
[33] Praaning-Van Dalen DP, DeLeeuw AM, Brouwer A, Knook DL. Rat
liver endothelial cells have a greater capacity than Kupffer cells to
endocytose yV-acetylglucosamineand mannose-terminated glycopro-
teins. Hepatology 1987;7:672–9.
[34] Decuzzi P, Ferraric M. The role of specific and non-specific
interactions in receptor-mediated endocytosis of nanoparticles. Bio-
materials 2007;28:2915–22.
